Chinese
Japan
English
On 11th August 2021,GenScript ProBio and Hefei TG ImmunoPharma Corporation Limited (TG ImmunoPharma ) started collaboration on innovative antibody drug research and development. GenScript ProBio will provide complete integrated CDMO services from preclinical pharmacological development to IND filing for TG ImmunoPharma , offering a variety of processes including fed-batch and perfusion process to accelerate the IND process. In the future ,GenScript ProBio and TG ImmunoPharma will collaborate on 10 CMC projects within 3 years, and GenScript ProBio will be the preferred partner for clinical and commercial production in these projects.
The innovative antibody drug program of TG ImmunoPharma is based on basic research on natural killer cells (NK cells) by the team of Chinese Academy of Engineering Academician Tian Zhigang from the University of Science and Technology of China. The team of Chinese Academy of Engineering Academician Tian Zhigang is one of the world’s leading teams in NK cell research, with a history of more than 30 years of conducting NK cell research and more than 20 years of discovering the pharmacological value of NK cell receptors. TG ImmunoPharma is committed to identifying effective inhibitory receptors for NK cell depletion to validate their potential as targets for tumor immunotherapy, and developing innovative antibody drugs on the global stage.
“Relying on the scientific research accumulation of the team of Chinese Academy of Engineering Academician Tian Zhigang, TG ImmunoPharma is a global leader as a drug development platform in the fields of immune checkpoint inhibitors and immunomodulators targeting NK cells,” said Dr. Brian Min, CEO of GenScript ProBio, “we believe that this collaboration will further exhibit the strengths of our technology and platform. We are looking forward to working with TG ImmunoPharma to promote the transformation of scientific research results on NK cells and create valuable anti-cancer antibody drugs on the global stage for the early benefit of cancer patients, depending on comprehensive quality management system and professional quality management and regulatory team of GenScript ProBio.”
Dr. Zhou Wenqiang, CEO of TG ImmunoPharma, said, “We are committed to finding another cancer killer - an inhibitory receptor for NK cell depletion - and developing “innovative antibody drugs on the global stage. We are pleased to be able to leverage the leading international platform and professional team of TG ImmunoPharma to drive the project from preclinical pharmaceutical research to IND filing. We are looking forward to working with GenScript ProBio to accelerate the process of industrialization.”
TG ImmunoPharma is a new R&D organization established based on the basic scientific research achievements made by the team of Chinese Academy of Engineering Academician Tian Zhigang from the University of Science and Technology of China, one of the world’s leading teams in NK cell research, with a history of more than 30 years of conducting NK cell research and more than 20 years of discovering the pharmacological value of NK cell receptors. Hefei TG ImmunoPharma has a global leading R&D technology platform in the fields of immune checkpoint inhibitors, dual/multifunctional antibodies, and immunomodulators for NK cells. Based on a solid foundation and accumulated strength, the team of TG ImmunoPharma will try its best to build an immune drug development and research base in Hefei Economic and Technological Development Zone and implement industrialization projects to help form pharmaceutical industry clusters, by integrating industry resources and promoting the transformation of world-class scientific research results concerning NK cell immune drugs.
GenScript ProBio is a biopharmaceutical contract development manufacture organization (CDMO) under GenScript. As a one-stop biologics R&D platform, it is mainly committed to providing end-to-end services from target development to commercial production for antibody drugs, cell and gene therapy drugs.
GenScript ProBio possesses a one-stop antibody development solution covering antibody discovery (hybridoma technology, phage display antibody library technology, whole human animal platform, bispecific antibody technology, single B-cell screening platform), antibody engineering (humanization, druggenerating evaluation and optimization, affinity maturation) and antibody evaluation (biological activity, physicochemical) and other antibody services. In terms of preclinical pharmaceutical development of antibody drugs, GenScript ProBio provides customers with integrated CDMO services including cell line development, host cell commercial licensing, upstream & downstream process development, analytical method development, and clinical sample production. It adopts various techniques such as fed-batch culture and perfusion culture to accelerate the IND process, supplies high-quality materials for clinical trials, and has successfully delivered a number of CMC and GMP production projects.
GenScript ProBio 's integrated gene cell therapy solution covers non-registration trials, process development, registration trails and plasmid virus commercial production at all stages. Its sophisticated quality system ensures the compliance, data authenticity and traceability requirements be well met in every stage.
Guided by the principle of "Collaboration push forward innovation", GenScript ProBio has always been committed to helping our customers cut the time for biologics to enter the clinical stage, to therefore reduce their R&D costs significantly, accelerate the translation process of medicines. In this way, GenScript ProBio aims to build a healthy future through joint efforts with its customers.